Efficacy and Safety of Trimodulin (BT588) in Subjects With Moderate or Severe COVID-19
Status:
Not yet recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
The main objectives of the trial are to assess the efficacy and safety of trimodulin as
adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult
hospitalized subjects with moderate or severe COVID-19.
Other objectives are to determine pharmacokinetic (PK) and pharmacodynamic (PD) properties of
trimodulin.